Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

Stock Information for Esperion Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Esperion Therapeutics Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
Esperion to Report Third Quarter 2024 Financial Results on November 7
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.